Cardiovascular Drugs Practice Questions

Q: A 45-year-old man with dilated cardiomyopathy and atrial fibrillation presents with a rapid ventricular rate. An agent is used to control the ventricular rate, but it also affects cardiac contractility. Which agent was most likely used?

Verapamil. **Explanation:** The clinical objective in this patient is **rate control** for atrial fibrillation. The question specifies that the agent used not only controls the ventricular rate but also significantly affects **cardiac contractility**. **1. Why Verapamil is correct:** Verapamil is a non-dihydropyridine Calcium Channel Blocker (CCB) that acts on the L-type calcium channels in the AV node and the myocardium. It is a potent **negative inotrope** (decreases contractility) and **negative chronotrope/dromotrope**. In a patient with dilated cardiomyopathy, Verapamil can acutely worsen heart failure due to this profound depressant effect on myocardial contractility, making it a high-yield contraindication in such cases. **2. Why the other options are incorrect:** * **Digoxin:** While it is used for rate control in AF (by increasing vagal tone at the AV node), it is a **positive inotrope**. It increases contractility, which contradicts the question's premise of an agent that negatively affects it. * **Nifedipine:** This is a dihydropyridine CCB. It acts primarily on vascular smooth muscle (vasodilation) and has **minimal to no effect** on the AV node or cardiac contractility at clinical doses. It is not used for rate control. * **Amiodarone:** While it can be used for rhythm/rate control, its effect on contractility is much less significant compared to Verapamil. It is often the preferred agent in patients with heart failure because it is relatively "heart-failure friendly." **Clinical Pearls for NEET-PG:** * **Verapamil & Diltiazem** are contraindicated in Heart Failure with Reduced Ejection Fraction (HFrEF) due to negative inotropy. * **Drug of choice** for rate control in AF with Heart Failure: **Digoxin or Beta-blockers** (cautiously). * **Drug of choice** for rate control in AF with WPW syndrome: **Procainamide** (Avoid ABCD: Atenolol, Beta-blockers, CCBs, Digoxin).

Q: Which of the following drugs is NOT useful in acute myocardial infarction?

Nifedipine. In the management of Acute Myocardial Infarction (AMI), the primary goal is to restore perfusion and reduce myocardial oxygen demand. **Why Nifedipine is NOT useful (and potentially harmful):** Nifedipine is a short-acting dihydropyridine calcium channel blocker. It causes potent peripheral vasodilation, which triggers **reflex tachycardia** and increased sympathetic activity. This increases myocardial oxygen demand and can worsen ischemia or even extend the infarct. Large clinical trials (like the SPRINT study) demonstrated that short-acting nifedipine increases mortality in AMI patients. Therefore, it is contraindicated in the acute phase of MI. **Why the other options are used:** * **Aspirin:** An antiplatelet agent that inhibits thromboxane A2 synthesis. It is the first-line drug given immediately to prevent further thrombus propagation and has been shown to significantly reduce mortality. * **ACE Inhibitors (e.g., Enalapril, Ramipril):** These are started within 24 hours of an MI. They prevent **ventricular remodeling**, reduce afterload, and decrease the risk of heart failure and subsequent mortality. * **Metoprolol:** A cardioselective beta-blocker. It reduces heart rate, contractility, and blood pressure, thereby decreasing myocardial oxygen demand. It also reduces the risk of post-MI arrhythmias (ventricular fibrillation). **High-Yield Clinical Pearls for NEET-PG:** * **Diltiazem/Verapamil:** These non-dihydropyridines may be used in AMI *only* if beta-blockers are contraindicated and there is no heart failure. * **Mnemonic for AMI Management:** **MONA** (Morphine, Oxygen, Nitroglycerin, Aspirin). * **ACE Inhibitors** are most beneficial in patients with anterior wall MI or those with an ejection fraction <40%.

Q: A 53-year-old woman presents with a history of hypertension. On follow-up, she is found to be hypertensive again and is prescribed hydralazine, a beta-blocker, and furosemide. She takes no other medications. She complains of muscle aches, joint pain, and a rash. Physical examination reveals a temperature of 37.7°C (100.0°F) and a scaling erythematous rash on her face. Laboratory investigations show positive antinuclear antibodies (ANA) and positive anti-histone antibodies. What is the most likely diagnosis?

Hydralazine-induced lupus erythematosus. ### Explanation **Correct Answer: B. Hydralazine-induced lupus erythematosus** The patient presents with the classic triad of **Drug-Induced Lupus Erythematosus (DILE)**: fever, arthralgia (joint pain), and a rash, following the initiation of **Hydralazine**. The definitive diagnostic clues in this clinical vignette are: 1. **Pharmacological Trigger:** Hydralazine is a well-known cause of DILE. It is often prescribed with a beta-blocker (to prevent reflex tachycardia) and a diuretic (to prevent fluid retention), as seen in this patient. 2. **Serology:** The presence of **Anti-histone antibodies** is highly specific ( >95%) for DILE. While Antinuclear Antibodies (ANA) are positive, **Anti-dsDNA antibodies** (typical of idiopathic SLE) are usually absent. 3. **Metabolism:** Hydralazine is metabolized via **Phase II acetylation**. "Slow acetylators" are at a significantly higher risk of developing this condition. **Why incorrect options are wrong:** * **Option A:** While the symptoms overlap with Systemic Lupus Erythematosus (SLE), the strong association with a specific drug, the presence of anti-histone antibodies, and the absence of renal/CNS involvement point specifically to DILE. * **Options C & D:** Neither beta-blockers nor furosemide are recognized triggers for drug-induced lupus. **High-Yield NEET-PG Pearls:** * **Common Drugs causing DILE (Mnemonic: SHIP):** **S**ulfonamides, **H**ydralazine, **I**soniazid, **P**rocainamide (highest risk). Others include Phenytoin and Minocycline. * **Key Serology:** Anti-histone antibodies (+) is the hallmark; Anti-dsDNA (-) and normal complement levels help differentiate it from idiopathic SLE. * **Clinical Presentation:** Unlike idiopathic SLE, DILE rarely involves the kidneys or the Central Nervous System. * **Management:** Symptoms typically resolve spontaneously upon **discontinuation** of the offending drug.

Q: All of the following are used in atrial arrhythmias except:

Lignocaine. **Explanation:** The correct answer is **Lignocaine (Lidocaine)**. The fundamental principle in treating arrhythmias is understanding the site of action of the drug. Lignocaine is a **Class IB antiarrhythmic** that acts by blocking activated and inactivated sodium channels. Its unique pharmacological property is its high affinity for channels in the **ventricular myocardium**, especially in ischemic or depolarized tissues. It has negligible effects on the atrial myocardium and the AV node, making it **ineffective for atrial arrhythmias** (like atrial fibrillation or flutter). It is primarily used for ventricular tachycardia and arrhythmias following myocardial infarction. **Why the other options are used in atrial arrhythmias:** * **Digoxin:** A cardiac glycoside that increases vagal tone, slowing conduction through the AV node. It is used for **rate control** in atrial fibrillation and flutter. * **Verapamil:** A Class IV antiarrhythmic (Calcium Channel Blocker) that slows AV nodal conduction and prolongs the refractory period. It is a first-line agent for terminating **Paroxysmal Supraventricular Tachycardia (PSVT)** and controlling rate in atrial fibrillation. * **Quinidine:** A Class IA antiarrhythmic that blocks sodium channels and has some potassium channel blocking activity. It can be used for the **rhythm control** (conversion and maintenance) of atrial fibrillation. **High-Yield Clinical Pearls for NEET-PG:** * **Lignocaine** is the drug of choice for **ventricular arrhythmias** occurring during cardiac surgery or post-MI, but it is ineffective when given orally due to high first-pass metabolism. * **Adenosine** is the drug of choice for the acute termination of PSVT. * **Amiodarone** is a "broad-spectrum" antiarrhythmic effective for both atrial and ventricular arrhythmias.

Q: Which among the following drugs is NOT used orally?

Lignocaine. **Explanation:** The correct answer is **Lignocaine** (Lidocaine). **1. Why Lignocaine is the correct answer:** Lignocaine is a Class IB antiarrhythmic drug that is **not administered orally** because it undergoes **extensive first-pass metabolism** in the liver (nearly 70%). If taken orally, its bioavailability is too low to reach therapeutic plasma concentrations, and its metabolites can increase the risk of central nervous system toxicity. Therefore, it is administered intravenously (for arrhythmias) or topically/locally (as an anesthetic). **2. Analysis of Incorrect Options:** * **Verapamil (Option B):** A Class IV Calcium Channel Blocker used for supraventricular tachycardia, hypertension, and angina. Although it has a significant first-pass effect, it is available in oral formulations with adjusted dosages. * **Phenytoin (Option C):** A Class IB antiarrhythmic (specifically for digoxin-induced arrhythmias) and an antiepileptic. It has good oral bioavailability and is commonly used in tablet or suspension form. * **Quinidine (Option D):** A Class IA antiarrhythmic drug. It is well-absorbed from the gastrointestinal tract and is administered orally for the maintenance of sinus rhythm in patients with atrial fibrillation/flutter. **3. High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Lignocaine is the drug of choice for **ventricular arrhythmias** occurring post-myocardial infarction (though amiodarone is now often preferred in ACLS protocols). * **Toxicity:** Lignocaine toxicity primarily affects the CNS, presenting as seizures, tremors, or blurred vision. * **Other non-oral drugs:** Remember that **Bretylium** and **Adenosine** are also antiarrhythmics that are not given orally (Adenosine has a half-life of <10 seconds and must be given as a rapid IV bolus). * **Mexiletine:** This is a Class IB analogue of lignocaine that *is* orally effective because it resists first-pass metabolism.

Q: Which of the following statements is true about esmolol?

All of the above.. **Explanation:** Esmolol is a unique, ultra-short-acting **cardioselective (β1-selective)** adrenergic antagonist. It is characterized by its rapid onset and very short duration of action (half-life of approximately 9 minutes) due to its metabolism by **red blood cell esterases**. * **Option A (No ISA):** Esmolol is a pure antagonist. It lacks intrinsic sympathomimetic activity (ISA), meaning it does not partially stimulate beta-receptors. This makes it highly effective at reducing heart rate and myocardial oxygen demand. * **Option B (Cardioselective):** It primarily blocks β1 receptors located in the heart. While selectivity is lost at very high doses, at therapeutic levels, it has minimal effect on β2 receptors in the bronchi or peripheral vasculature. * **Option C (Precipitate Heart Failure):** Like all beta-blockers, esmolol is a **negative inotrope**. By reducing the force of myocardial contraction, it can acutely worsen cardiac output in patients with compensated heart failure or borderline hemodynamics, potentially precipitating acute heart failure. Since all three statements are pharmacologically accurate, **Option D** is the correct answer. **High-Yield Clinical Pearls for NEET-PG:** * **Metabolism:** It is the only beta-blocker metabolized by **plasma esterases** (not liver or kidney), making it safe in hepatic or renal failure. * **Indications:** Preferred for intraoperative tachycardia/hypertension, supraventricular arrhythmias (SVT), and hypertensive emergencies (especially aortic dissection). * **Administration:** Given only via **intravenous (IV)** route because of its rapid metabolism. * **Mnemonic:** Remember the **"B-E-A-M"** for cardioselective blockers: **B**isoprolol, **E**smolol, **A**tenolol, **M**etoprolol.

Q: Which class of drugs is considered a myocardial re-infarction inhibitor?

Beta blockers. **Explanation:** **Why Beta Blockers are Correct:** Beta-blockers (e.g., Metoprolol, Atenolol, Carvedilol) are the mainstay for secondary prevention post-Myocardial Infarction (MI). They act by competitively inhibiting $\beta_1$ receptors in the heart, leading to decreased heart rate, contractility, and systolic blood pressure. This significantly reduces **myocardial oxygen demand**. Furthermore, they increase diastolic perfusion time, improving coronary blood flow. By reducing "cardiac work" and preventing catecholamine-induced arrhythmias and ventricular remodeling, they have been clinically proven to reduce the risk of re-infarction and sudden cardiac death, thereby increasing long-term survival. **Why Other Options are Incorrect:** * **Nitrates:** While excellent for acute symptomatic relief of angina (preload reduction), they do not modify the disease process or reduce the incidence of re-infarction or mortality. * **Calcium Channel Blockers (CCBs):** Although they cause vasodilation, they are generally not first-line post-MI. Short-acting dihydropyridines (like Nifedipine) can actually cause reflex tachycardia, which may worsen ischemia. * **Potassium Channel Openers:** Drugs like Nicorandil are used for stable angina but lack robust clinical evidence for preventing re-infarction compared to Beta-blockers. **NEET-PG High-Yield Pearls:** * **TIMI Study:** Confirmed the benefit of early Beta-blocker administration in MI. * **Contraindications:** Avoid Beta-blockers in patients with bradycardia, high-grade AV block, severe active asthma, or cardiogenic shock. * **Cardioselective agents:** $\beta_1$ selective blockers (A-M: **A**tenolol, **B**isoprolol, **M**etoprolol) are preferred to minimize bronchospasm. * **Mortality Benefit:** Along with Beta-blockers, ACE inhibitors, Antiplatelets (Aspirin/Clopidogrel), and Statins are the four pillars that reduce mortality post-MI.

Q: A 69-year-old woman is being treated for dysrhythmias with quinidine. Select the most likely side effects to occur.

Prolonged QT interval. **Explanation:** **Quinidine** is a prototype **Class IA antiarrhythmic** drug. Its primary mechanism of action involves blocking open sodium ($Na^+$) channels, but it also significantly blocks **delayed rectifier potassium ($K^+$) channels**. 1. **Why Option B is Correct:** By blocking potassium channels during phase 3 of the cardiac action potential, quinidine delays repolarization. This results in an **increase in the Action Potential Duration (APD)** and a **prolonged QT interval** on the ECG. A prolonged QT interval is a critical clinical concern as it predisposes patients to *Torsades de Pointes* (a polymorphic ventricular tachycardia). 2. **Why Other Options are Incorrect:** * **A & D (Sensory loss/Action tremor):** These are not associated with quinidine. While lidocaine (Class IB) can cause CNS toxicity (paresthesia/tremors), quinidine’s neurological profile is different. * **C (Parkinsonism):** This is typically caused by dopamine antagonists (e.g., antipsychotics or metoclopramide), not antiarrhythmics. **High-Yield Clinical Pearls for NEET-PG:** * **Cinchonism:** A classic triad of side effects unique to quinidine (and quinine) including tinnitus, dizziness, and headache. * **Vagolytic Effect:** Quinidine has antimuscarinic properties that can increase AV conduction; it is often co-administered with digoxin or a beta-blocker to prevent paradoxical tachycardia in atrial fibrillation. * **Drug Interaction:** Quinidine reduces the renal clearance of **Digoxin**, leading to digitalis toxicity. * **Diarrhea:** The most common gastrointestinal side effect (seen in ~30% of patients).

Question 1

A 45-year-old man with dilated cardiomyopathy and atrial fibrillation presents with a rapid ventricular rate. An agent is used to control the ventricular rate, but it also affects cardiac contractility. Which agent was most likely used?

Accepted Answer

Verapamil

Answer

Digoxin

Answer

Nifedipine

Answer

Amiodarone

Question 2

Which of the following drugs is NOT useful in acute myocardial infarction?

Accepted Answer

Nifedipine

Answer

Aspirin

Answer

ACE inhibitors

Answer

Metoprolol

Question 3

A 53-year-old woman presents with a history of hypertension. On follow-up, she is found to be hypertensive again and is prescribed hydralazine, a beta-blocker, and furosemide. She takes no other medications. She complains of muscle aches, joint pain, and a rash. Physical examination reveals a temperature of 37.7°C (100.0°F) and a scaling erythematous rash on her face. Laboratory investigations show positive antinuclear antibodies (ANA) and positive anti-histone antibodies. What is the most likely diagnosis?

Accepted Answer

Hydralazine-induced lupus erythematosus

Answer

Systemic lupus erythematosus

Answer

Beta-blocker-induced systemic lupus erythematosus

Answer

Furosemide-induced systemic lupus erythematosus

Question 4

All of the following are used in atrial arrhythmias except:

Accepted Answer

Lignocaine

Answer

Digoxin

Answer

Verapamil

Answer

Quinidine

Question 5

Which drug prolongs life in a patient with chronic stable angina?

Accepted Answer

Beta Blocker

Answer

Aspirin

Answer

Calcium Channel Blocker

Answer

ACE inhibitor

Question 6

Which among the following drugs is NOT used orally?

Accepted Answer

Lignocaine

Answer

Verapamil

Answer

Phenytoin

Answer

Quinidine

Question 7

Which of the following statements is true about esmolol?

Accepted Answer

All of the above.

Answer

It has no intrinsic sympathomimetic activity.

Answer

It is a cardioselective beta-blocker.

Answer

It can precipitate heart failure.

Question 8

Which class of drugs is considered a myocardial re-infarction inhibitor?

Accepted Answer

Beta blockers

Answer

Nitrates

Answer

Calcium channel blockers

Answer

Potassium channel openers

Question 9

Which one of the following is the most appropriate drug to use for the patient described in parentheses?

Accepted Answer

Captopril (60-year-old woman with diabetic nephropathy)

Answer

Nitroprusside (50-year-old man with BP of 140/95)

Answer

Losartan (29-year-old pregnant woman)

Answer

Propranolol (40-year-old patient with peripheral vascular disease)

Question 10

A 69-year-old woman is being treated for dysrhythmias with quinidine. Select the most likely side effects to occur.

Accepted Answer

Prolonged QT interval

Answer

Sensory loss

Answer

Parkinsonism-like symptoms

Answer

Action tremor

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?